Critical vasospasm during fingolimod (fty720) treatment in a patient with multiple sclerosis
We report on a woman who developed critical arterial vasospasm of the left arm within 7 days after having started treatment with Fingolimod (FTY720). Fingolimod is an orally administered modulator of the sphingosine-1-phosphate (S1P) receptor family, acting at 4 of the 5 G protein-coupled S1P recept...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 14, 2010
|
| In: |
Neurology
Year: 2010, Volume: 74, Issue: 24, Pages: 2022-2024 |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0b013e3181e3972b |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1212/WNL.0b013e3181e3972b Verlag, lizenzpflichtig, Volltext: https://n.neurology.org/content/74/24/2022 
|
| Author Notes: | A. Schwarz, M. Korporal, W. Hosch, R. Max, B. Wildemann |
| Summary: | We report on a woman who developed critical arterial vasospasm of the left arm within 7 days after having started treatment with Fingolimod (FTY720). Fingolimod is an orally administered modulator of the sphingosine-1-phosphate (S1P) receptor family, acting at 4 of the 5 G protein-coupled S1P receptors. It causes a reversible sequestration of lymphocytes into lymph nodes, thereby inhibiting their migration to sites of inflammation. Fingolimod is currently tested in clinical trials for the treatment of relapsing-remitting multiple sclerosis (RRMS). As S1P receptors regulate numerous cellular processes in different tissues, Fingolimod exhibits the capacity to induce versatile pharmacologic effects. |
|---|---|
| Item Description: | Gesehen am 06.07.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0b013e3181e3972b |